Karlyn Martin, MD, M.S.

Associate Professor of Medicine, Division of Hematology and Oncology

Hematologist, UVM Health Network

PRONOUNS She/Her

A person with brown hair wearing a white coat

89 Beaumont Ave
Given E214
Larner College of Medicine at the University of Vermont
Burlington, VT 05405
United States
Pronouns She/Her
Alma mater(s)
  • M.D., Northwestern University Feinberg School of Medicine
  • M.S., Northwestern University
  • B.A., Yale University
Affiliated Department(s)

Department of Medicine, Division of Hematology and Oncology 

Dr. Martin's UVM Health Network Provider Page

Dr. Martin's UVM Cancer Center Member Profile

Area(s) of expertise

  • Anemias
  • Classical Hematology
  • Leukopenia
  • Thrombocytopenia
  • Thrombosis
  • Venous Thromboembolism
  • Myeloproliferative Neoplasm 

BIO

Dr. Karlyn Martin is an Associate Professor of Medicine and Health Services researcher within the Division of Hematology/Oncology at the University of Vermont Larner College of Medicine. Her clinical practice and research focus are in classical hematology. Her research interests are to improve the quality and delivery of care for patients with non-malignant hematologic conditions; specifically, she focuses on the prevention and management of venous thromboembolism (VTE) in specialized populations, including those with obesity and cancer. She is a past Committee Co-Chair of the Venus Thromboembolism Network of the United States, VTE Treatment and Anticoagulation Management Committee. She currently serves as a Co-Chair, Scientific and Standardization Subcommittee on Hemostasis & Malignancy, International Society on Thrombosis and Haemostasis. 

Dr. Martin's postdoctoral training

Fellowship in Hematology and Medical Oncology, University of North Carolina Hospitals

Residency in Internal Medicine, McGaw Medicine Center of Northwestern University 

Dr. Martin's Recent Publications

  1. Martin KA, Holmes C. Time to move beyond risk assessment models for ambulatory cancer-associated thrombosis. Res Pract Thromb Haemost 2025; 102991.
  2. Martin KA, Cushman M. Factor V Leiden. JAMA. 2025 Jun 10;333(22):2013-2014. doi: 10.1001/jama.2025.2420. PMID: 40305030.
  3. Martin KA, Mininger CN. Words Matter: a Call to Remove "Sickler" from Medical Lingo in the United States. J Gen Intern Med. 2024 Sep 20. doi: 10.1007/s11606-024-09036-7. Epub ahead of print. PMID: 39302561.
  4. Ades S, Resnick Y, Barker J, Martin KA et al Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study. Lancet Reg Health Am 2024; 38: 100866.
  5. Martin KA, Cameron KA, Linder JA, et al. Preventing venous thromboembolism for ambulatory patients with cancer: Developing the form and content of implementation strategies. Thrombosis Update 2024; 15: 100168.
  6. Martin KA Cameron KA Lyleroehr MJ Linder J O’Brien MO Hirschhorn L. Venous thromboembolism prevention in cancer care: Implementation strategies to address underuse. Res Pract Thromb Haemost 2023 Aug 20;7(7):102173
  7. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP. DOAC compared with warfarin for VTE in low weight patients. Thromb Res 2023; 229: 146–148.
  8. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. J Thromb Thrombolysis. 2023 Feb 9. doi: 10.1007/s11239-023-02774-1. PMID: 36757644 

Publications

Dr. Martin's Publications on PubMed

Awards and Achievements

  • 2025: Co-Chair, Scientific and Standardization Subcommittee on Hemostasis & Malignancy, International Society on Thrombosis and Haemostasis 

Bio

Dr. Karlyn Martin is an Associate Professor of Medicine and Health Services researcher within the Division of Hematology/Oncology at the University of Vermont Larner College of Medicine. Her clinical practice and research focus are in classical hematology. Her research interests are to improve the quality and delivery of care for patients with non-malignant hematologic conditions; specifically, she focuses on the prevention and management of venous thromboembolism (VTE) in specialized populations, including those with obesity and cancer. She is a past Committee Co-Chair of the Venus Thromboembolism Network of the United States, VTE Treatment and Anticoagulation Management Committee. She currently serves as a Co-Chair, Scientific and Standardization Subcommittee on Hemostasis & Malignancy, International Society on Thrombosis and Haemostasis. 

Dr. Martin's postdoctoral training

Fellowship in Hematology and Medical Oncology, University of North Carolina Hospitals

Residency in Internal Medicine, McGaw Medicine Center of Northwestern University 

Dr. Martin's Recent Publications

  1. Martin KA, Holmes C. Time to move beyond risk assessment models for ambulatory cancer-associated thrombosis. Res Pract Thromb Haemost 2025; 102991.
  2. Martin KA, Cushman M. Factor V Leiden. JAMA. 2025 Jun 10;333(22):2013-2014. doi: 10.1001/jama.2025.2420. PMID: 40305030.
  3. Martin KA, Mininger CN. Words Matter: a Call to Remove "Sickler" from Medical Lingo in the United States. J Gen Intern Med. 2024 Sep 20. doi: 10.1007/s11606-024-09036-7. Epub ahead of print. PMID: 39302561.
  4. Ades S, Resnick Y, Barker J, Martin KA et al Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study. Lancet Reg Health Am 2024; 38: 100866.
  5. Martin KA, Cameron KA, Linder JA, et al. Preventing venous thromboembolism for ambulatory patients with cancer: Developing the form and content of implementation strategies. Thrombosis Update 2024; 15: 100168.
  6. Martin KA Cameron KA Lyleroehr MJ Linder J O’Brien MO Hirschhorn L. Venous thromboembolism prevention in cancer care: Implementation strategies to address underuse. Res Pract Thromb Haemost 2023 Aug 20;7(7):102173
  7. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP. DOAC compared with warfarin for VTE in low weight patients. Thromb Res 2023; 229: 146–148.
  8. Martin KA, Lancki N, Li C, Eyster ME, Sanfilippo K, Woller IA, Woller SC, Kreuziger LB, Rosovsky RP. DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network. J Thromb Thrombolysis. 2023 Feb 9. doi: 10.1007/s11239-023-02774-1. PMID: 36757644 

Publications

Dr. Martin's Publications on PubMed

Awards and Achievements

  • 2025: Co-Chair, Scientific and Standardization Subcommittee on Hemostasis & Malignancy, International Society on Thrombosis and Haemostasis